Acute mountain sickness Injury, Occupational Diseases, Poisoning Acute mountain sickness
Conditions
Interventions
1. Sumatriptan succinate 50 mg plus orally, once at early ascent
2. Placebo: similar color, shape, and weight to interventional group
Sponsors
Imam Neurology Research Center (Iran)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age of 18 to 60 years 2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres 3. Consenting participant 4. May reasonably be expected to complete a 24 hour trial
Exclusion criteria
Exclusion criteria: 1. Other neuro-vascular disease such as cerebrovascular accident, and hypoxic cerebral damage 2. Cardiovascular disease such as ischaemic heart disease, coronary artery disease, significant valvular disease, congestive heart failure, and uncontrolled hypertension with systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg 3. Pregnancy 4. Hypersensitivity to either sumatriptan or acetazolamide or their components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AMS development due to Lake Louise criteria within 24 hours (International Hypoxia Symposium) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. AMS severity (score more than or equal to five) due to Lake Louise protocol after 24 hours (self-report and clinical assessment) 2. Altitude headache occurrence and severity | — |
Countries
Iran
Outcome results
None listed